Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionTranscriptional coactivator cooperating with nuclear hormone receptors to potentiate transcriptional activation. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating a calcium-dependent release of a repressor complex and a recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves a release of HDAC1 and recruitment of CREBBP. Belongs to the neural progenitors-specific chromatin remodeling complex (npBAF complex) and the neuron-specific chromatin remodeling complex (nBAF complex). During neural development a switch from a stem/progenitor to a post-mitotic chromatin remodeling mechanism occurs as neurons exit the cell cycle and become committed to their adult state. The transition from proliferating neural stem/progenitor cells to post-mitotic neurons requires a switch in subunit composition of the npBAF and nBAF complexes. As neural progenitors exit mitosis and differentiate into neurons, npBAF complexes which contain ACTL6A/BAF53A and PHF10/BAF45A, are exchanged for homologous alternative ACTL6B/BAF53B and DPF1/BAF45B or DPF3/BAF45C subunits in neuron-specific complexes (nBAF). The npBAF complex is essential for the self-renewal/proliferative capacity of the multipotent neural stem cells. The nBAF complex along with CREST plays a role regulating the activity of genes essential for dendrite growth. SMARCA4/BAF190A may promote neural stem cell self-renewal/proliferation by enhancing Notch-dependent proliferative signals, while concurrently making the neural stem cell insensitive to SHH-dependent differentiating cues (By similarity). Also involved in vitamin D-coupled transcription regulation via its association with the WINAC complex, a chromatin-remodeling complex recruited by vitamin D receptor (VDR), which is required for the ligand-bound VDR-mediated transrepression of the CYP27B1 gene. Acts as a corepressor of ZEB1 to regulate E-cadherin transcription and is required for induction of epithelial-mesenchymal transition (EMT) by ZEB1.
Tissue specificityColocalizes with ZEB1 in E-cadherin-negative cells from established lines, and stroma of normal colon as well as in de-differentiated epithelial cells at the invasion front of colorectal carcinomas (at protein level).
Involvement in diseaseDefects in SMARCA4 are the cause of rhabdoid tumor predisposition syndrome type 2 (RTPS2) [MIM:613325]. RTPS2 is a familial cancer syndrome predisposing to renal or extrarenal malignant rhabdoid tumors and to a variety of tumors of the central nervous system, including choroid plexus carcinoma, medulloblastoma, and central primitive neuroectodermal tumors. Rhabdoid tumors are the most aggressive and lethal malignancies occurring in early childhood.
Global transcription activator homologous sequence antibody
global transcription activator snf2l4 antibody
Homeotic gene regulator antibody
Mitotic growth and transcription activator antibody
Nuclear protein GRB1 antibody
Protein brahma homolog 1 antibody
Protein BRG-1 antibody
Protein BRG1 antibody
SMARC A4 antibody
SNF2 beta antibody
SNF2 like 4 antibody
Sucrose nonfermenting like 4 antibody
SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily A member 4 antibody
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 antibody
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 4 antibody
Transcription activator BRG1 antibody
Anti-BRG1 antibody [EPR3913] images
Western blot - Anti-BRG1 antibody [EPR3913] (ab92496)
Predicted band size : 185 kDa Additional bands at : 185 kDa. We are unsure as to the identity of these extra bands.
Lane 1: Wild-type HAP1 cell lysate (20 µg)
Lane 2: BRG1 knockout HAP1 cell lysate (20 µg)
Lane 3: K562 cell lysate (20 µg)
Lane 4: Molt-4 cell lysate (20 µg)
Lanes 1 - 4: Merged signal (red and green). Green - ab92496 observed at 185 kDa. Red - loading control, ab18058, observed at 124 kDa.
ab92496 was shown to recognize BRG1 when BRG1 knockout samples were used, along with additional cross-reactive bands. Wild-type and BRG1 knockout samples were subjected to SDS-PAGE. ab92496 and ab18058 (loading control to Vinculin) were diluted 1/1000 and 1/10000 respectively and incubated overnight at 4°C. Blots were developed with goat anti-rabbit IgG (H + L) and goat anti-mouse IgG (H + L) secondary antibodies at 1/10000 dilution for 1 hour at room temperature before imaging.
Western blot - BRG1 antibody [EPR3913] (ab92496)
All lanes : Anti-BRG1 antibody [EPR3913] (ab92496) at 1/1000 dilution
Lane 1 : K562 cell lysate Lane 2 : MOLT4 cell lysate
Lysates/proteins at 10 µg per lane.
Secondary goat anti-rabbit HRP at 1/2000 dilution
Predicted band size : 185 kDa
References for Anti-BRG1 antibody [EPR3913] (ab92496)
has not yet been referenced specifically in any publications.
Publishing research using ab92496? Please let us know so that we can cite the reference in this datasheet.
Concentration of lot no. is
Concentration not available for this lot.
Find concentration of your lot:
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"